Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder

NCT00417118 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00417118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00417118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
April 30, 2008
Enrollment
365 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety